Conakry

Despite a recent sharp drop in the overall number of Ebola cases, the situation remains precarious in West Africa

NATURE MAGAZINE  by Declan Butler                                                                    Feb. 24, 2015
More than a year since the start of one of the worst public health crises in recent history, Ebola cases have been tumbling in West Africa. But the epidemic is far from over: the risk of flare ups and further geographical spread will remain until there are no new cases.

The ease in case numbers means that public-health countermeasures and resources can be shifted in many places, from curbing runaway outbreaks to aggressively targeting the remaining, often smaller outbreaks....

At the same time, there is a danger of complacency. Reducing the number of cases to zero demands identifying and breaking all new chains of transmission, a task that still faces major obstacles—not least the fast approaching rainy season.

Highlighting the precariousness of the current situation, on February 20, the officials leading the United Nations' Ebola response efforts warned that the gains of the past few months risked unravelling.

AFP                                                                                                                     Feb. 23, 2015
Los Angeles  - Early results from an Ebola trial using the experimental drug Avigan (favipiravir) showed Monday it was somewhat effective at saving lives if given early in the illness, but not later.

Early results from an Ebola trial using the experimental drug Avigan (favipiravir) show it is somewhat effective at saving lives if given early in the illness (AFP Photo/George Frey)

The antiviral treatment is being developed by the Japanese company Toyama Chemical, and has been shown safe and effective against some other viruses including influenza, West Nile and yellow fever.

An ongoing clinical trial in Guinea is testing the drug's use in patients with the Ebola virus, which causes severe vomiting, diarrhea and sometimes fatal bleeding.

Results from only 80 people are available so far, but they show that among those who received the drug early in their illness, 15 percent died of Ebola.

Read complete story.

NEW YORK TIMES  by Rick Gladstone                                    Feb. 20, 2015

The top two health officials managing the Ebola epidemic cast doubt Friday on a pledge by West African leaders to reduce new cases to zero by mid-April, and expressed concern about a possible rebound of the disease.

REUTERS    by Tom Miles                             FeB. 20, 2015
GENEVA --The World Health Organization has approved the first rapid test for Ebola in a potential breakthrough for ending an epidemic that has killed almost 10,000 people in West Africa, it said on Friday.

The test, developed by U.S. firm Corgenix Medical Corp, is less accurate than the standard test but is easy to perform, does not require electricity, and can give results within 15 minutes, WHO spokesman Tarik Jasarevic said.

"It's a first rapid test. It's definitely a breakthrough," he said.

The standard laboratory test has a turnaround time of 12-24 hours. While the Corgenix test is not failsafe, it could quickly identify patients who need quarantine and make it much easier to verify rapidly any new outbreaks.

Read complete story.

http://www.reuters.com/article/2015/02/20/us-health-ebola-testing-idUSKBN0LO0R920150220